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Purpose/Objective: There are general international 
recommendations about introducing checklists in medical 
procedures to reinforce patient safety. Specifically, 
Intraoperative Radiotherapy with electrons (IOERT) is one of 
these medical procedures thats bring together anesthetic, 
surgical and radiotherapy procedures. Therefore, our aim is 
to present the design and implementation of various 
checklists for IOERT treatments with patient transportation. 
We adopted a multidisciplinary point of view with the 
objective of obtain a safety tool that allows greater control 
in different areas and stages, which the whole procedure 
comprises. 
Materials and Methods: A leading team consisting of a 
medical physicist, an anesthesiologist, a scrub nurse and a 
radiation oncologist was set. The team determined which 
items will be checked, and decided that the lists should be 
clear and concise. Furthermore, checklists were adjusted to 
the different areas involved in the procedure. The initial 
scheme was based on a convenient content to be verified and 
the timeouts for verifications. 
Results: As a result, five checklists were obtained for every 
area of specialization which recorded the whole process of 
patient treatment. These lists correspond to the areas of: 
Medical Physics, Radio-Surgical-Anesthesia, Radiation 
Nursing, Scrub Nursing and Radiation Therapists. It was 
determined that the best way of synchronizing the lists was 
to consider the location of the patient all the time. 
Therefore, the process is divided into three main sections, 
corresponding to the three theatres where the patient is 
during the treatment at our center. The first one is the 
surgery in the operating room, the second one is the way 
between the operating room and the linear accelerator 
bunker, and the last one is the bunker. In every section, 
different blocks are specified. After every block there is a 
timeout to verify it. On average, the lists has 33 items and 5 
timeouts.Thus, the procedure is interrupted as less as 
possible. In those blocks where transport occurs, there are a 
doble checks for the outward and return to the operating 
room. 
The lists were tested and checked by other professionals 
during real cases of rectal neoplasms, soft tissue sarcomas 
and breast. They made changes and improvements. It was 
decided to plasticize the lists and fill them in with pen to 
protect them from dirt and olso to make them more 
manageable. They spent about 90 man-hours. 
 
Conclusions: The multidisciplinary work allows to implement 
a checklist also in the field of IOERT. The decision to use the 
patient's location with regard to transportation, as a link 
between the lists, was helpful for harmonizing and 
interconnecting them, because the lists are different due to 
the different nature of the tasks, but all have the same 
structure. The verification is optimized when the number of 
blocks and timeout is minimal. The set of this checklists 
presented proved to be invaluable in ensuring safety by 
themselves and reinforce the quality of treatment along with 
other actions. 
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Purpose/Objective: Targeted intraoperative radiation 
therapy (IORT) as an alternative to whole breast irradiation 
has been described for patients with early-stage breast 
cancer. The randomized phase III TARGiT trial demonstrated 
similar recurrence rates to WBI and a lower overall toxicity 
profile on short-term follow-up. We report on our early Latin 
American surgical experience using the Intrabeam 
radiotherapy delivery system. 
Materials and Methods: Prospectively gathered estrogen 
receptor-positive, clinically node-negative patients with 
invasive breast cancer < 2.5 cm receiving using the Intrabeam 
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system were reviewed. IORT-related effects and early 
postoperative outcome were assessed.  
Results: Seventy eight patients (median age 67 years) 
underwent lumpectomy, sentinel lymph node biopsy, and 
concurrent IORT from march 2013 to march 2014. Ninety-five 
percent of patients had invasive ductal histology with a 
median tumor size of 1.5 cm.  
Conclusions: While a variety of APBI techniques are currently 
available for clinical use, our early Latin American operative 
experience with IORT shows it is well tolerated with low 
morbidity. The addition of WBI may be necessary in situations 
for positive residual margins or microscopic nodal disease in 
patients who do not undergo additional surgery. 
Implementation of IB impacts treatment planning and 
operating room use in a multidisciplinary breast cancer 
program. The safety profile, ease of administration, and 
reduced costs of IB favor its more widespread use in selected 
patients with early-stage breast cancer. 
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Purpose/Objective: The Intrabeam system is a miniature 
accelerator emitting a 50 kV isotropic radiation. Its flat and 
surface applicators convert a spherical dose distribution into 
a flat one. This study aims at characterizing the dosimetric 
behaviour of these applicators for dermatologic applications. 
Materials and Methods: Dosimetric characterization was 
carried out in two steps. Firstly characterization was made in 
standard conditions for dermatologic applications, which is 
with the applicator directly on contact with the skin. 
Secondly, characterization was made in more clinical 
conditions, with obliquities and heterogeneities. 
Results: Behaviours of flat and surface applicators are 
different and have already been studied before. In standard 
conditions, dose rates and dose distribution results differ 
from previously published studies due to differences in the x-
ray source design. The study showed that when contact 
between the applicator and the skin of the patient is not 
perfect there is a dose distribution spread on the edge of the 
irradiation field where the contact is not made. Dose loss due 
to lack of backscatter radiations is significant. By contrast, 
influence of a denser material behind the measurement point 
has no significant influence on the dose at this point. 
Thickness of tissue treated with flat and surface applicators 
is only a few millimetres, depending on the applicator's size. 
Conclusions: The INTRABEAM® system with surface and flat 
applicators is a reliable way of treating superficial cutaneous 
malignancies as long as there is a good contact between the 
applicator and the skin.  
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Purpose/Objective: The main purpose of this study was to 
investigate the capability of EBT3 Gafchromic films to 
measure the delivered dose to the tumour bed and skin for 
intraoperative radiotherapy under clinical conditions in order 
to implement a protocol for in vivo dosimetry. 
Materials and Methods: This work has been performed using 
the 50 kV X-ray source from the Intrabeam® instrument (Carl 
Zeiss, Germany). EBT3 Gafchromic films were characterised 
within a water phantom and then used for in vivo dosimetry.  
Results: EBT3 Gafchromic films were found to be feasible for 
in vivo dosimetry. Measurements were performed in 10 
patients resulting in measured doses from 9.04 to 17.71 Gy in 
the tumour bed and from 0.87 to 3.98 Gy on the skin.  
Conclusions: EBT3 Gafchromic films offered an accurate 
method for the measurement of both the tumour bed and 
skin.  
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Purpose/Objective: Head and neck squamous cell carcinoma 
(HNSCC) is frequently characterized by overexpression of 
anti-apoptotic Bcl-2 family members. Increased levels of 
these anti-apoptotic proteins has been associated with radio- 
and chemoresistance and poor clinical outcome. Inhibition of 
anti-apoptotic Bcl-2 family members therefore represents an 
appealing strategy to overcome resistance to anticancer 
therapies. The aim of this study was to show enhanced 
radiation-induced tumor cell kill in HNSCC tumor cell lines in 
vitro, upon combined treatment with the pan-Bcl-2 inhibitor 
AT-101 and radiation. Additionally, we aimed to compare the 
effective in vitro concentrations with human serum levels of 
AT-101 obtained from a phase I/II trial, to substantiate 
therapeutic opportunities. 
